Published in Mol Cell Proteomics on January 20, 2010
Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet (2011) 2.02
Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma. Mol Syst Biol (2012) 1.54
Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. Mol Cell Proteomics (2010) 1.41
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clin Transl Med (2014) 1.05
Proteomic profiling of Mycobacterium tuberculosis identifies nutrient-starvation-responsive toxin-antitoxin systems. Mol Cell Proteomics (2013) 1.05
Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. J Extracell Vesicles (2013) 1.01
Whole gel processing procedure for GeLC-MS/MS based proteomics. Proteome Sci (2013) 0.94
Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics (2012) 0.93
Proteomics for discovery of candidate colorectal cancer biomarkers. World J Gastroenterol (2014) 0.89
Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer (2013) 0.87
EMILIN2 (Elastin microfibril interface located protein), potential modifier of thrombosis. Thromb J (2011) 0.86
Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics. PLoS One (2011) 0.85
Nuclear matrix proteome analysis of Drosophila melanogaster. Mol Cell Proteomics (2010) 0.82
Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance. Mol Cell Proteomics (2013) 0.81
The spectra count label-free quantitation in cancer proteomics. Cancer Genomics Proteomics (2012) 0.81
Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture. Proteome Sci (2014) 0.81
Subnuclear domain proteins in cancer cells support the functions of RUNX2 in the DNA damage response. J Cell Sci (2015) 0.81
Sorbitol dehydrogenase overexpression and other aspects of dysregulated protein expression in human precancerous colorectal neoplasms: a quantitative proteomics study. Mol Cell Proteomics (2014) 0.80
Proteomic Profiling of Bifidobacterium bifidum S17 Cultivated Under In Vitro Conditions. Front Microbiol (2016) 0.78
Multi-omics profile of the mouse dentate gyrus after kainic acid-induced status epilepticus. Sci Data (2016) 0.77
Large scale systematic proteomic quantification from non-metastatic to metastatic colorectal cancer. Sci Rep (2015) 0.77
Dissecting characteristics and dynamics of differentially expressed proteins during multistage carcinogenesis of human colorectal cancer. World J Gastroenterol (2016) 0.76
Exosomal sorting of the viral oncoprotein LMP1 is restrained by TRAF2 association at signalling endosomes. J Extracell Vesicles (2015) 0.76
Cirrhosis related functionality characteristic of the fecal microbiota as revealed by a metaproteomic approach. BMC Gastroenterol (2016) 0.75
Exome sequencing of a colorectal cancer family reveals shared mutation pattern and predisposition circuitry along tumor pathways. Front Genet (2015) 0.75
OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages. Clin Proteomics (2017) 0.75
Proteomic indicators of oxidation and hydration state in colorectal cancer. PeerJ (2016) 0.75
Chemical composition and the potential for proteomic transformation in cancer, hypoxia, and hyperosmotic stress. PeerJ (2017) 0.75
Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem (1996) 45.70
Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem (2002) 35.30
A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem (2003) 29.58
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res (2002) 16.02
Genetic instability in colorectal cancers. Nature (1997) 12.51
STRING 7--recent developments in the integration and prediction of protein interactions. Nucleic Acids Res (2006) 12.16
Directed proteomic analysis of the human nucleolus. Curr Biol (2002) 7.04
Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2006) 6.64
Large-scale proteomic analysis of the human spliceosome. Genome Res (2002) 5.75
Nuclear structure in cancer cells. Nat Rev Cancer (2004) 5.12
BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res (2005) 4.72
APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer (2001) 4.54
Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell (2000) 3.91
Nuclear membrane proteins with potential disease links found by subtractive proteomics. Science (2003) 3.64
Epithelial cytoskeletal framework and nuclear matrix-intermediate filament scaffold: three-dimensional organization and protein composition. J Cell Biol (1984) 3.48
Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell (2009) 3.18
Proteomics of organelles and large cellular structures. Nat Rev Mol Cell Biol (2005) 2.98
Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat Protoc (2006) 2.52
Actin up in the nucleus. Nat Rev Mol Cell Biol (2004) 2.13
Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease. Nucleic Acids Res (1998) 2.06
Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome. Mol Cell Biol (2008) 1.93
Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology (2002) 1.91
The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. Annu Rev Cell Dev Biol (2004) 1.90
Lamin proteins form an internal nucleoskeleton as well as a peripheral lamina in human cells. J Cell Sci (1995) 1.85
Nuclear matrix proteins reflect cell type of origin in cultured human cells. Proc Natl Acad Sci U S A (1988) 1.85
Nestin structure and predicted function in cellular cytoskeletal organisation. Histol Histopathol (2005) 1.80
Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut (2008) 1.77
On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics (2009) 1.74
CHMP1 is a novel nuclear matrix protein affecting chromatin structure and cell-cycle progression. J Cell Sci (2001) 1.62
The nuclear matrix revealed by eluting chromatin from a cross-linked nucleus. Proc Natl Acad Sci U S A (1997) 1.55
What the nucleolus says to a tumour pathologist. Histopathology (2009) 1.38
Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice. Carcinogenesis (2009) 1.38
Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer (1999) 1.37
Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol (1996) 1.36
Dimerization of FIR upon FUSE DNA binding suggests a mechanism of c-myc inhibition. EMBO J (2007) 1.32
Clinical proteomics: personalized molecular medicine. JAMA (2001) 1.30
Systematic genome-wide annotation of spliceosomal proteins reveals differential gene family expansion. Genome Res (2005) 1.28
Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res (1989) 1.24
Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther (2009) 1.12
Deciphering the human nucleolar proteome. Mass Spectrom Rev (2006) 1.11
Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res (2000) 1.10
Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res (2006) 1.06
Systems biology in the cell nucleus. J Cell Sci (2005) 1.04
High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch (2009) 1.04
A-type nuclear lamins act as transcriptional repressors when targeted to promoters. Exp Cell Res (2009) 1.03
NMPdb: Database of Nuclear Matrix Proteins. Nucleic Acids Res (2005) 0.98
Fatal connections: when DNA ends meet on the nuclear matrix. J Cell Biochem Suppl (2000) 0.98
Unravelling the nuclear matrix proteome. J Proteomics (2008) 0.98
High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res (2002) 0.98
Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem (2008) 0.97
Phosphorylation of the N-terminal domain regulates subcellular localization and DNA binding properties of the peptidyl-prolyl cis/trans isomerase hPar14. J Mol Biol (2003) 0.95
HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha. Nucleic Acids Res (2009) 0.92
MLPAnalyzer: data analysis tool for reliable automated normalization of MLPA fragment data. Cell Oncol (2008) 0.92
Galectin-3 stabilizes heterogeneous nuclear ribonucleoprotein Q to maintain proliferation of human colon cancer cells. Cell Mol Life Sci (2009) 0.89
Parvulin (Par14), a peptidyl-prolyl cis-trans isomerase, is a novel rRNA processing factor that evolved in the metazoan lineage. Mol Cell Proteomics (2009) 0.89
High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery. Biomark Med (2007) 0.88
Nuclear matrix proteins as proteomic markers of preneoplastic and cancer lesions : commentary re: G. Brunagel et al., nuclear matrix protein alterations associated with colon cancer metastasis to the liver. Clin. Cancer Res., 8: 3039-3045, 2002. Clin Cancer Res (2002) 0.87
Role of the nuclear matrix proteins in malignant transformation and cancer diagnosis. Exp Oncol (2004) 0.85
Actin, myosin, cytokeratins and spectrin are components of the guinea pig sperm nuclear matrix. Tissue Cell (2005) 0.80
Resolving the resolution of array CGH. Genomics (2007) 3.66
BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res (2006) 3.32
Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology (2008) 3.18
Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res (2008) 3.06
Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet (2005) 2.71
Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.66
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol (2006) 2.33
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst (2009) 2.22
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
PPIB mutations cause severe osteogenesis imperfecta. Am J Hum Genet (2009) 2.16
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res (2006) 2.15
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol (2010) 1.90
Somatic mutations and deletions of the E-cadherin gene predict poor survival of patients with gastric cancer. J Clin Oncol (2013) 1.89
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res (2009) 1.78
Direct visualization by cryo-EM of the mycobacterial capsular layer: a labile structure containing ESX-1-secreted proteins. PLoS Pathog (2010) 1.76
On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics (2009) 1.74
Gold-enhanced biomolecular surface imaging of cells and tissue by SIMS and MALDI mass spectrometry. Anal Chem (2006) 1.71
Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer (2010) 1.69
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res (2008) 1.69
Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut (2010) 1.68
Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat (2009) 1.65
Proteomics analysis of rat brain postsynaptic density. Implications of the diverse protein functional groups for the integration of synaptic physiology. J Biol Chem (2003) 1.56
Higher fecal immunochemical test cutoff levels: lower positivity rates but still acceptable detection rates for early-stage colorectal cancers. Cancer Epidemiol Biomarkers Prev (2010) 1.55
Colorectal cancer epigenetics: complex simplicity. J Clin Oncol (2011) 1.47
Direct molecular imaging of Lymnaea stagnalis nervous tissue at subcellular spatial resolution by mass spectrometry. Anal Chem (2005) 1.46
Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol (2004) 1.46
Smoothing waves in array CGH tumor profiles. Bioinformatics (2009) 1.45
Risk of colorectal cancer in patients with Barrett's esophagus: A Dutch population-based study. Am J Gastroenterol (2009) 1.44
Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J Proteome Res (2010) 1.42
Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol (2005) 1.40
Genomic profiling of gastric cancer predicts lymph node status and survival. Oncogene (2003) 1.40
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res (2011) 1.40
Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta (2010) 1.38
Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol (2010) 1.34
Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol (2012) 1.30
Composition of the type VII secretion system membrane complex. Mol Microbiol (2012) 1.29
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol (2011) 1.27
Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett's neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc (2010) 1.27
Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer (2008) 1.26
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. Genes Chromosomes Cancer (2008) 1.25
Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas. Cancer Prev Res (Phila) (2011) 1.23
Rapid quantification of myocardial fibrosis: a new macro-based automated analysis. Cell Oncol (Dordr) (2011) 1.22
Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol (2003) 1.21
Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene (2003) 1.20
Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study. BMC Cancer (2010) 1.20
KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn (2012) 1.19
Subcellular imaging mass spectrometry of brain tissue. J Mass Spectrom (2005) 1.16
Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol (2010) 1.16
Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res (2005) 1.16
Imaging mass spectrometry at cellular length scales. Nat Protoc (2007) 1.15
TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut (2011) 1.15
Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan. Gastroenterology (2011) 1.15
The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother (2006) 1.14
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One (2008) 1.14
iTRAQ-based proteomics profiling reveals increased metabolic activity and cellular cross-talk in angiogenic compared with invasive glioblastoma phenotype. Mol Cell Proteomics (2009) 1.14
Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis (2009) 1.12
Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis. Genes Chromosomes Cancer (2012) 1.10
Automated serum peptide profiling using novel magnetic C18 beads off-line coupled to MALDI-TOF-MS. Proteomics Clin Appl (2007) 1.10
Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr) (2014) 1.09
Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin Cancer Res (2002) 1.08
Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One (2009) 1.06
Proteomic profiling of Mycobacterium tuberculosis identifies nutrient-starvation-responsive toxin-antitoxin systems. Mol Cell Proteomics (2013) 1.05
Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter (2010) 1.05
Phosducin-like proteins in Dictyostelium discoideum: implications for the phosducin family of proteins. EMBO J (2003) 1.05
Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics (2010) 1.04
High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch (2009) 1.04
Candidate driver genes in focal chromosomal aberrations of stage II colon cancer. J Pathol (2010) 1.03
Specific chaperones for the type VII protein secretion pathway. J Biol Chem (2012) 1.03
Proteomics in colorectal cancer translational research: biomarker discovery for clinical applications. Clin Biochem (2012) 1.03